Skip to content

Impact of Dried Moringa Oleifera Leaves in Enhancing Hemoglobin Status

Impact of Dried Moringa Oleifera Leaves as Value Added Supplement in Enhancing Hemoglobin Status of Reproductive Aged Females of Low Socio-economic Group

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03514472
Enrollment
34
Registered
2018-05-02
Start date
2013-01-31
Completion date
2014-04-30
Last updated
2018-05-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Anemia, Iron Deficiency

Keywords

Hb, Anemia,

Brief summary

This research project is aimed at combating the nutritional deficiencies (Iron deficiency anemia) of reproductive aged females belonging to the underprivileged group of the society. Since anemia is one of the causes of still child-birth, preterm and low birth weight babies causing cognitive disabilities during the later years of life, So, it needs to be treated on priority bases.

Detailed description

Mal-nutrition is a significant problem in the developing world, with serious consequences for human health and socio-economic development. It is estimated that over 43% women of reproductive age suffer from anemia. In Pakistan, about 35% non-pregnant and 51% pregnant women are suffering from anemia. Prevention and control against anemia rely on iron supplementation and food fortification on large scale. Both these methods are not affordable and feasible for poor people. Previous studies have shown that about 97% females do not meet their iron requirements. The possible reason to this can be iron losses from body including menstruation. To overcome these problems, culturally accepted, inexpensive and modified recipes were used to supply iron with addition of Moringa oleifera leaves (rich and cheap source of iron). In the study 34 of ages between 13-30 years were selected (excluding pregnant and lactating women) and were intervened with value added supplement Moringa oleifera for a period of three months. These recipes were made part of the diet by giving a dose of three meals per day on regular basis. Each recipe contained about 15 g of Dried Moringa powder. After the intervention, out of total 34, 3 females achieved normal Hb level of 12 g/dl. Overall, 94% cases of the study showed improvement of 1.8 g/dl (on average) in Hb level after intervention. There was a significant increase in blood Hb level (p\<0.000) and both the var5iables were strongly and positively correlated (0.928). Variables of age and levels of education were weakly but significantly related to each other (p\<0.001) in improving Hb after intervention. Females with higher levels of education showed better response towards intervention. After intervention with Moringa oleifera, an average increase of 1.5 g/dl in Hb was observed in the entire population whereas, members of Group B (ages above 18) showed more increase of 14.96% in their Hb level as compared to members of Group A (ages below 18) showing an increase of 12.96% in Hb level.

Interventions

DIETARY_SUPPLEMENTDried Moringa oleifera leaves

Sponsors

Kinnaird College for Women
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

In the study 34 of ages between 13-30 years divided into 2 age groups (below and above 18) were selected (excluding pregnant and lactating women) and were intervened with value added supplement Moringa oleifera for a period of three months.

Eligibility

Sex/Gender
FEMALE
Age
13 Years to 30 Years
Healthy volunteers
No

Inclusion criteria

* Reproductive aged females (13-30 years)

Exclusion criteria

* pregnant and Lactating women

Design outcomes

Primary

MeasureTime frameDescription
Improvement in Hemoglobin status3 monthsComparison of Hb levels pre and post intervention

Secondary

MeasureTime frameDescription
Changes in BMI5 monthsChanges in BMI after improvement in Hb status

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026